High flying LinkGevity wins Investment from Francis Crick Institute
Based at Babraham Research Campus and affiliated with the University of Cambridge, LinkGevity has been chosen for Crick’s celebrated KQ Labs Programme.
The AI-driven company is focused on age-related diseases and longevity and its first-in-class anti-necrotic therapeutic is set for clinical trials for kidney disease and accelerated ageing.
Its technology is literally on a different planet! LinkGevity was picked as one of only 12 companies globally for the NASA/Microsoft Space-Health Program, due to its anti-necrotic’s™ potential in preventing accelerated ageing and tissue degeneration in astronauts.
The “earth landing’ involvement with the KQ Labs Programme promises to be equally ‘stellar.’ It provides participants with an unspecified equity investment and access to an advanced global scientific network. Only 10 startups are chosen annually after a rigorous due diligence process.
Designed to propel world-class healthcare innovation, LinkGevity’s therapeutic data, innovative approach and scientific leadership secured its place in the cohort. Dr Carina Kern, CEO and co-founder of LinkGevity, said: “Being selected for the KQ Labs Programme is a tremendous honour. This programme will be pivotal to our plans, which include initiating a clinical trial for kidney disease, the 9th leading cause of death globally according to the WHO.
“What is additionally exciting is that the kidney provides an accelerated ageing model to validate this drug as a candidate to treat ageing more broadly – paving the way for a potentially landmark trial.”
Serena Kern-Libera, LinkGevity’s COO and co-founder, added: “We are thrilled to be selected for the prestigious KQ Labs Programme, a recognition that underscores the growing excitement around our innovative Anti-Necrotic therapeutic.
“Building on the momentum from our successful inclusion in the NASA/Microsoft Space-H programme where we were selected for the potential of our drug to alleviate accelerated ageing in astronauts, being part of the wider Francis Crick Institute ecosystem will help propel our research.”
Guided by its proprietary Blueprint Theory of Ageing – developed by Carina in collaboration with leading doctors and longevity experts – LinkGevity identifies and targets key pathological pathways. These are the molecular source of destructive cascades underlying multiple age-related conditions.
By precisely targeting these pathological pathways with broad-spectrum therapeutics, LinkGevity aims to halt age-related decline.
The company’s flagship therapeutic is a first-in-class Anti-Necrotic™, which targets one such pathological pathway – necrosis. It has earned a prestigious Horizon Europe grant from the European Union alongside UK government funding.
LinkGevity plans to initiate a flagship clinical trial later this year, on the treatment of tissue degeneration in the kidney and associated ageing and disease – the ninth leading cause of death in the world today according to the WHO – and broadening from there to other age-related indications.
